All Posts

Deploying Precision Medicine to Treat Rheumatoid Arthritis

ABS CEO Eugene Williams joined Force Family Office for a webinar on precision medicine, biomarker-guided diagnosis, and ABS's immuno-corrective approach to autoimmune disease. ABS CEO Eugene Williams recently joined Force Family Office for a webinar on ABS's precision approach to autoimmune disease — an approach rooted in precision medicine, not broad immunosuppression. Today, 30–50% of patients with rheumatoid arthritis, lupus, type 1 diabetes, and other autoimmune diseases

Jul 21 min read

Autoimmunity BioSolutions Co-Founder Dr. Mariano A. Garcia-Blanco Elected President of the RNA Society

Recognized For His Leadership in RNA Biology and the Scientific Foundation Driving Precision Autoimmune Disease Therapeutics, Dr. Garcia-Blanco continues to advance RNA-driven disease mechanisms. Autoimmunity BioSolutions (ABS), a biotechnology company developing a personalized, genetically guided immuno-corrective therapy designed to normalize elevated levels of soluble IL7 receptor (sIL7R), today announced that company co-founder Dr. Mariano A. Garcia-Blanco has been electe

Jun 102 min read

Autoimmunity BioSolutions Co-Founder Dr. Mariano A. Garcia-Blanco Inducted into the National Academy of Sciences

May 200 min read

Autoimmunity BioSolutions Expands Seed Funding Round and Deepens Family Office Participation

May 140 min read

ABS announced key appointments to its leadership team, including Richard Polisson, MD, MHSc, Chief Medical Officer, and Jen Beachell, MBA, Chief Business Officer.

Nov 20, 20250 min read

Autoimmunity BioSolutions raises $2M Series Seed to advance development of a next generation, immuno-corrective therapy for autoimmune disease treatment

Nov 22, 20240 min read